Trial Profile
A Multicenter, Open, Randomized, 24 Weeks Study to Evaluate the Superiority of Glimepiride Over Sitagliptin for the Treatment of naive Patients With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2010
Price :
$35
*
At a glance
- Drugs Glimepiride (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SUMER
- Sponsors Sanofi
- 29 Nov 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 29 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Aug 2010 Planned end date changed from 1 Jul 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.